Drug Information

Drug (ID: DG02004) and It's Reported Resistant Information

• Name: Icariin-Curcumol
• Indication:
  In total 1 Indication(s)
  . .; .

Type(s) of Resistant Mechanism of This Drug

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Prostate cancer [ICD-11: 2C82]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: AKT serine/threonine kinase 1 (AKT1) [1]

• Metabolic Type: Glucose metabolism
• Sensitive Disease: Prostate cancer [ICD-11: 2C82.0]
• Molecule Alteration: .; .
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: PI3K-Akt signaling pathway; Activation; hsa04151
• In Vivo Model: Male BALB/c nude mice, LNCaP cells; Mice
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: Our evidence revealed that Icariin-Curcumol attenuated DTX resistance through modulation of the PI3K-Akt pathway and the Warburg effect and that Icariin-Curcumol and DTX have synergistic effects.

References

• Ref 1: Icariin-Curcumol promotes docetaxel sensitivity in prostate cancer through modulation of the PI3K-Akt signaling pathway and the Warburg effect. Cancer Cell Int. 2023 Sep 2;23(1):190.